张晶.免疫检查点抑制剂相关暴发性心肌炎的研究进展[J].内科急危重症杂志,2022,28(6):444-447
扫码阅读全文
|
| DOI：10.11768/nkjwzzzz20220602 |
| 中文关键词: 免疫检查点抑制剂 免疫相关不良事件 心血管毒副作用 暴发性心肌炎 |
| 英文关键词: |
| 基金项目:中国医学科学院医学与健康科技创新工程项目（2022-I2M-JB-007）;国家自然科学基金（82170397）;中央高水平医院临床科研业务费（2022-PUMCH-A-182,2022-PUMCH-B-098）;中央高校基本科研业务费（3332022112） |
|
| 摘要点击次数: 1457 |
| 全文下载次数: 1590 |
| 中文摘要: |
| 摘要 免疫检查点抑制剂（ICI）通过阻断肿瘤细胞的免疫逃逸，恢复机体T淋巴细胞的抗肿瘤活性而显著改善了恶性肿瘤患者的生存率，是近年来肿瘤治疗领域革命性的突破。但是ICI的作用并非特异性地针对肿瘤细胞，其诱发的免疫反应过度活跃可能会导致多种组织器官的免疫相关不良事件，其中ICI相关暴发性心肌炎发生率虽低，但病情进展迅速，死亡率极高。随着ICI药物适应证的持续增加和用药患者规模的愈加庞大，预计ICI相关暴发性心肌炎的发生率也会随之增加，因此临床医生对该疾病应充分认识。本文综述了近年来ICI相关暴发性心肌炎的流行病学、发病机制及临床诊治等领域的研究进展。 |
| 英文摘要: |
| Abstract The advent of immune checkpoint inhibitors (ICI) has revolutionized the treatment of malignant tumors, which can restore the anti-tumor activity of T-lymphocytes by blocking tumor cell immune escape, thus significantly improving the survival of patients with malignant tumors. However, ICI do not specifically target tumor cells, and they can also cause immune-related adverse events in a variety of tissues and organs by inducing an overactive immune response. Although the incidence of ICI-related fulminant myocarditis is low, the disease progresses rapidly with a high mortality rate. As the number of patients taking ICI continues to grow, cases of ICI-associated fulminant myocarditis are expected to increase. Therefore, clinicians should be fully aware of it. This article reviews the epidemiology, pathogenesis, and clinical management of ICI-associated fulminant myocarditis in recent years. |
|
